Efficacy of live lactobacillus preparations in treating cervical inflammation and clearing viral infections in patients with HPV infection complicated by bacterial vaginosis

Abstract

This study aimed to evaluate the efficacy and safety of Dingjunsheng, a live Lactobacillus preparation, as adjuvant therapy in patients
with human papillomavirus (HPV) infection complicated by bacterial vaginosis (BV). A retrospective analysis was conducted on
152 eligible patients, randomly divided into two groups: the observation group (n=87) receiving standard BV antibacterial therapy
plus Dingjunsheng, and the control group (n=65) who received standard BV antibacterial therapy alone. The patients were followed
up for six months. Primary outcomes included HPV clearance rate and cervical cytological inflammation improvement, while
secondary outcomes involved BV recurrence rate and adverse reaction incidence. The results showed that the observation group had
a significantly higher HPV clearance rate (73.6% vs 53.9%) and inflammation improvement rate (90.8% vs 76.9%), as well as a
lower BV recurrence rate (3.1% vs 13.9%) compared to the control group. Dingjunsheng was identified as an independent protective
factor for HPV clearance (OR=2.5, 95%CI:1.3–5.1). The incidence of adverse reactions was similar between both groups. We
conclude that Dingjunsheng adjuvant therapy demonstrated effectiveness in improving HPV clearance, alleviating inflammation,
and reducing BV recurrence, with good safety, making it a valuable treatment strategy for these patients.